Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Phase 2Active Not RecruitingNCT03718767

National Cancer Institute (NCI)62 enrolled

Overview

Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). If there are a high number of mutations in a tumor, it is called hypermutator phenotype (HMP). The drug nivolumab helps the immune system fight cancer. Researchers think it can be more effective in patients with IDH1 or IDH2 mutated gliomas with HMP. They will test gliomas with and without HMP. Objectives: To see if nivolumab stops tumor growth and prolongs the time that the tumor is controlled. Eligibility: Adults 18 years or older with IDH1 or IDH2 mutated gliomas Design: Participants will be screened with: Medical history Physical exam Heart, blood, and pregnancy tests Review of symptoms and activity levels Brain magnetic resonance imaging (MRI). Participants will lie in a cylinder that takes pictures in a strong magnetic field. Tumor samples Participants will get the study drug in 4-week cycles. They will get it through a small plastic tube in a vein (intravenous \[IV\]) on days 1 and 15 of cycles 1-4. For cycles 5-16, they will get it just on day 1. On days 1 and 15 of each cycle, participants will repeat some or all screening tests. After cycle 16, participants will have 3 follow-up visits over 100 days. They will answer health questions, have physical and neurological exams, and have blood tests. They may have a brain MRI. Participants whose disease did not get worse but who finished the study drug within 1 year of treatment may have imaging studies every 8 weeks for up to 1 year. Participants will be called or emailed every 6 months with questions about their health.

BACKGROUND: * Glioma is the most common malignant brain tumor. Genes coding for isocitrate dehydrogenases 1and 2 (IDH1 and IDH2), metabolic enzymes, are frequently mutated in gliomas, particularly lower-grade gliomas (LGGs). IDH1/2 mutation causes a unique tumor biology, including the accumulation of 2-hydroxyglutarate (2-HG), an oncometabolite, which in turn causes genomic hypermethylation and tumorigenesis. * IDH-mutant LGGs undergo a slow but unremitting progression to higher grade transformation (HT) and eventually become high grade gliomas (HGGs) with a significant increase in the number of somatic mutations. A subset of patients with transformed HGGs develop a hypermutator phenotype (HMP), possibly related, but not limited, to previous treatment with alkylating agents and radiotherapy. The mechanisms of this clinical phenomenon are not fully understood, and no effective treatments are available for the HMP HGGs. * High tumor mutation burden (TMB) is a characteristic finding in many of the transformed tumors. Furthermore, this increased mutation burden, with commensurate increase in neoantigen expression, may be correlated with a better response to immune checkpoint inhibitor (ICPIs) treatment. * Nivolumab is a monoclonal antibody that binds to the programmed cell death protein 1 (PD1) receptor and blocks its interaction with programmed death-ligand 1 (PD L1) and PD L2 and subsequently releasing PD 1 pathway mediated inhibition of the immune response, including antitumor immune response. * The United States (US) Food and Drug Administration granted approval to nivolumab for the treatment of unresectable or metastatic melanoma, advanced non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck, locally advanced or metastatic urothelial carcinoma, microsatellite instability-high or mismatched repair deficient metastatic colorectal cancer and hepatocellular carcinoma. * The first randomized clinical trial in glioblastoma with nivolumab (CheckMate-143) was completed in early 2017. Unfortunately, the study didn't meet its primary endpoint of improved overall survival over bevacizumab monotherapy. The objective response rate (ORR) was lower in nivolumab arm than bevacizumab arm. However, the response with nivolumab was more durable. The safety profile of nivolumab was very consistent with what has been observed in other tumor types. OBJECTIVE: -To determine the 6-month progression free survival rate in IDH-mutant gliomas patients with and without HMP in responses to nivolumab treatment. ELIGIBILITY: * Patients with diffuse glioma, confirmed by National Cancer Institute (NCI) Laboratory of Pathology * Age greater than or equal to 18 years * Karnofsky Performance Scale (KPS) greater than or equal to 60% * IDH 1 or IDH 2 mutation confirmed by deoxyribonucleic acid (DNA) sequencing * Patients must have TMB status performed at National Institutes of Health (NIH) * Tumor tissue or slides should be available for molecular and immune profiling DESIGN: * This study is an open label phase II clinical trial of the immune checkpoint inhibitor, nivolumab, in patients with HMP and non-hypermutated phenotype (NHMP) IDH-mutant gliomas. * Patients with HMP and NHMP will receive nivolumab at a standard dose of 240 mg intravenously every 2 weeks for cycles 1-2, then doses of 480 mg every 4 weeks for cycles 3-16. A maximum of 20 treatments will be given (16 cycles). * A maximum of 29 patients with IDH-mutant glioma with HMP (Cohort 1) and 30 patients with NHMP (Cohort 2) will be evaluated. * A Simon's optimal two-stage design will be used to conduct the HMP arm and the NHMP arm independently. For the HMP cohort, in stage I, a total number of 10 patients are accrued. If 9 or more patients progress by 6 months, the cohort will be terminated early; otherwise, additional 19 patients will be accrued in stage II, resulting in a total sample size of 29. Among these 29 patients, if 6 or more patients are progression-free at 6 months, we will claim that the treatment is promising for patients with HMP IDH-mutant gliomas. For NHMP cohort, in stage I, a total number of 15 patients are accrued. If 3 or more patients are progression-free at 6 months, the cohort will move to stage II and an additional 15 patients will be accrued in stage II, resulting in a total sample size of 30. Among these 30 patients, if 10 or more patients are progression-free at 6 months, we will claim that the treatment is promising for patients with NHMP IDH-mutant gliomas.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) mutation (confirmed by deoxyribonucleic acid (DNA) sequencing, Foundation One is preferable for confirmation of mutation, but not necessary). * Patients must have tumor specific mutation burden (number of somatic mutations per exome) tested at NIH: Must have either result of tumor mutation burden from the most recent surgical tumor sample or must provide adequate genomic materials of the sample for tumor testing. The tumor tissue (e.g., block or 15 unstained slides) must be available for molecular and immune profiling. Fresh or frozen tumor sample will be used if available, but not mandatory. * Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of nivolumab in patients \<18 years of age, children are excluded from this study but will be eligible for future pediatric trials. * Patient must be able to tolerate a magnetic resonance imaging (MRI) study with intravenous gadolinium contrast. * Karnofsky greater than or equal to 60% * Patients must have adequate organ and marrow function as defined below: * Absolute neutrophil count greater than or equal to 1,500/mcL * Platelet Count greater than or equal to 100,000/MCL * Hemoglobin greater than 9.0 g/dL (may be transfused to achieve this level) * Blood Urea Nitrogen (BUN) less than or equal to 30 mg/dL and * Serum creatinine less than or equal to 1.7 mg/dL * Total bilirubin (except patients with Gilbert's Syndrome, who are eligible for the study but exempt from the total bilirubin eligibility criterion) less than or equal to 2.0 mg/dL * Alanine aminotransferase (ALT) and aspartate aminotransaminase (AST) less than or equal to 2.5x institutional upper limit of normal. * The effects of nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and up to 5 months (women). Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. * The patient must be able to understand and be willing to sign a written informed consent document. EXCLUSION CRITERIA: * Patients who are receiving any other investigational agents. * Patients who have a history of receiving immune therapy. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab. * History of severe hypersensitivity reaction to any monoclonal antibody. * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years prior to initiation of study therapy. * Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), myasthenia gravis; systemic autoimmune disease such as Systemic Lupus Erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome. Such diseases should be excluded because of the risk of recurrence or exacerbation of disease. --Of note, patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible. * The patient must not be currently on a corticosteroid dose greater than dexamethasone 1 mg per day or its equivalent. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations (within timeframes identified in the bullets below) that would limit compliance with study requirements. * Known human immunodeficiency virus (HIV)-positive or acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS is based on the lack of information regarding the safety of nivolumab in patients with active HIV infection * Pregnant women are excluded from this study because nivolumab's potential for teratogenic or abortifacient effects is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab, breastfeeding should be discontinued if the mother is treated with nivolumab.

Outcomes

Primary Outcomes

Median Progression Free Survival (PFS) Rate at 6 Months

PFS is defined from the day of study entry until imaging is confirmed to show disease progression or death, whichever occurs first. Disease progression was assessed by the Immunotherapy Response Assessment neuro-oncology Criteria. Disease progression is \>25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new enhancing measurable lesion that exceeds a 25% increase in cross-sectional area; clear clinical deterioration not attributable to other causes apart from the tumor and/or failure to return for evaluation due to death or deteriorating condition. PFS was analyzed by the Kaplan-Meier method and is reported with a 95% confidence interval.

Time frame: 6 months

Secondary Outcomes

Mean Symptom Interference Score Per Treatment Cycle Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT)

Participant reported outcome measures using self-reported symptom interference with daily activities using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT). The MDSAI-BT 5-minute questionnaire uses an 11-point scale (0-10) to rate symptoms interference in the last 24 hours of a participant's life related to mood, work Inside and outside the home), relations with other people, walking and enjoyment of life. 0 = symptom not present and 10 = as bad as you can imagine. Higher score indicates more interference. Per protocol, MDSAIs are performed with imaging. If no imaging, no MDASI.

Time frame: Baseline and Cycles 2, 4, 6, 8, 10, 12, 14, and 16 (approximately 32 weeks +/- 3 days).

Mean Symptom Severity Score Per Treatment Cycle Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT)

Participant reported outcome measures using self-reported symptom severity with daily activities (e.g., work) using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) are reported for each treatment cycle. The MDSAI-BT 5-minute questionnaire uses an 11-point Likert scale (0-10). 0 = symptom not present and 10 = as bad as you can imagine. Higher score indicates worse severity. Per protocol, MDSAIs are performed with imaging. If no imaging, no MDASI.

Time frame: Baseline and Cycles 2, 4, 6, 8, 10, 12, 14, and 16 (approximately 32 weeks +/- 3 days).

Overall Survival

OS is defined as the time from treatment initiation to the time of death.

Time frame: Until the death of the last surviving participant, a median of 7.4 months in Cohort 1 and a median of 31.6 months in Cohort 2.

Tumor Mutation Burden

Tumor mutation Burden is measured using whole exome sequencing.

Time frame: During the screening period (14 days prior to study therapy)

Proportion of Participants Rating Symptoms 5 or Greater (on a 0-10 Scale) Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT)

The proportion of participants rating symptoms 5 or greater (on a 0-10 scale) was assessed using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT). The MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) 5-minute questionnaire uses an 11-point Likert scale (0-10) to measure symptoms reported by the participant. 0 = symptom not present and 10 = as bad as you can imagine. Higher score indicates worse severity.

Time frame: Baseline and Cycles 2, 4, 6, 8, 10, 12, 14, and 16 (approximately 32 weeks +/- 3 days).

Median Percentage of Participants That Have Progressive Disease At 12 Months

PFS was analyzed by the Kaplan-Meier method and is reported with a 95% confidence interval. PFS is defined from the day of study entry until imaging is confirmed to show disease progression. Disease progression was assessed by the Immunotherapy Response Assessment neuro-oncology Criteria. Disease progression is \>25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new enhancing measurable lesion that exceeds a 25% increase in cross-sectional area; clear clinical deterioration not attributable to other causes apart from the tumor and/or failure to return for evaluation due to death or deteriorating condition.

Time frame: At 12 months

Number of Participants Responses Received and Were Expected Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) Forms

Here is the number of participants with IDH-mutant gliomas with and without hypermutator phenotype, responses received and were expected using the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) forms. Received MDASI-BT forms will be checked versus the timing schedule and considered as valid if they fall within ten days of the scheduled assessment window. Compliance rates will be calculated as the number of received valid forms over the number of expected forms.

Time frame: Baseline and Cycles 2, 4, 6, 8, 10, 12, 14, and 16 (approximately 32 weeks +/- 3 days).

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes